Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Natalie M. Czuczman, Matthew J. Barth, Juan Gu, Vishala Neppalli, Cory Mavis, Sarah E. Frys, Qiang Hu, Song Liu, Pavel Klener, Petra Vockova, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri

Blood (2016) 127 (9): 1128–1137.

https://doi.org/10.1182/blood-2015-04-640920

Published: 2016

Includes: Supplemental data

Journal Articles

Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models

Sarah Frys, BSc, Natalie M Czuczman, BSc, Cory Mavis, BSc, MSc, Delphine C.M. Rolland, PharmD, PhD, Megan S Lim, MD PhD, Aradhana Tiwari, Mitchell S. Cairo, MD, Rodney R. Miles, MD PhD, Matthew J. Barth, MD

Blood (2014) 124 (21): 1769.

https://doi.org/10.1182/blood.V124.21.1769.1769

Published: 2014

Journal Articles

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Natalie M. Czuczman, BSc, Sarah Frys, BSc, Pavel Klener, Jr., MD, PhD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD

Blood (2013) 122 (21): 647.

https://doi.org/10.1182/blood.V122.21.647.647

Published: 2013

Journal Articles

The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models

Sarah Frys, BSc, Andrew Skomra, Natalie M Czuczman, BSc, Cory Mavis, BSc, MSc, Delphine C.M. Rolland, PharmD, PhD, Megan Lim, MD, PhD, Aradhana Awasthi, Ph.D, Mitchell S. Cairo, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2013) 122 (21): 5144.

https://doi.org/10.1182/blood.V122.21.5144.5144

Published: 2013

Journal Articles

Evaluation of the Anti-Tumor Activity of MLN4924, A Novel NEDD8 Activating Enzyme Inhibitor, in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma.

Natalie M Czuczman, Matthew J. Barth, MD, Richa Dwar, Cory Mavis, BSc, MSc, Pavel Klener, Jr., MD, PhD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2012) 120 (21): 2761.

https://doi.org/10.1182/blood.V120.21.2761.2761

Published: 2012

Journal Articles

Apoptotic and Non-Apoptotic Cellular Pathways Executed by Bortezomib (BTZ) in Rituximab-Resistant Lymphomas

Juan Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Cory Mavis, BSc, MSc, Natalie M Czuczman, Karen E Thudium, George Deeb, MD, John Gibbs, MD, Myron S. Czuczman, MD

Blood (2011) 118 (21): 4967.

https://doi.org/10.1182/blood.V118.21.4967.4967

Published: 2011

Journal Articles

The Novel Proteasome Inhibitor Carfilzomib (CFZ) Potentiates the Anti-Tumor Activity of Chemotherapeutic Agents in Rituximab-Chemotherapy Resistant Lymphoma Through Inducing G2/M Cell Cycle Arrest and Cell Death

Juan Gu, PhD, Natalie M Czuczman, Gregory P. Kaufman, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD

Blood (2011) 118 (21): 4970.

https://doi.org/10.1182/blood.V118.21.4970.4970

Published: 2011

Journal Articles

Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples

Matthew J. Barth, MD, Gopichand Pendurty, MD, Cory Mavis, BSc, MSc, Natalie M Czuczman, John Gibbs, MD, George Deeb, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2011) 118 (21): 4972.

https://doi.org/10.1182/blood.V118.21.4972.4972

Published: 2011

NARROW

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models

Evaluation of the Anti-Tumor Activity of MLN4924, A Novel NEDD8 Activating Enzyme Inhibitor, in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma.

Apoptotic and Non-Apoptotic Cellular Pathways Executed by Bortezomib (BTZ) in Rituximab-Resistant Lymphomas

The Novel Proteasome Inhibitor Carfilzomib (CFZ) Potentiates the Anti-Tumor Activity of Chemotherapeutic Agents in Rituximab-Chemotherapy Resistant Lymphoma Through Inducing G2/M Cell Cycle Arrest and Cell Death

Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only